Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors
Former Chairman, CEO and Founder of ChemoCentryx, Inc. Former Chairman, CEO and Founder of ChemoCentryx, Inc.…
53,200€
0,90%
Echtzeit-Aktienkurs ChemoCentryx Inc.
Bid:
Ask:
Nachrichten zur ChemoCentryx Inc. Aktie
XFRA : CAPITAL ADJUSTMENT INFORMATION - 21.10.2022 - US16383L1061
Das Instrument US16383L1061 CHEMOCENTRYX INC. EQUITY wird ex Kapitalmassnahme gehandelt am 21.10.2022
The instrument US16383L1061 CHEMOCENTRYX INC. EQUITY is traded ex…
XFRA : 2CX: Aussetzung/Suspension
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME …
XFRA : Deletion of Instruments from Boerse Frankfurt - 20.10.2022
The following instruments on Boerse Frankfurt do have their last trading day on 20.10.2022
Die folgenden Instrumente in Boerse Frankfurt haben…
Form 8-K ChemoCentryx, Inc. For: Oct 20
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
XFRA : INSTRUMENT_SUSPENSION - US16383L1061
Instrument ID [8439] (2CX - US16383L1061) suspended...…
ChemoCentryx shareholders approve $4.7B merger with Amgen
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Is ChemoCentryx (CCXI) Stock Outpacing Its Medical Peers This Year?
Here is how ChemoCentryx (CCXI) and Eiger BioPharmaceuticals (EIGR) have performed compared to their sector so far this year....…
ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid…